L-dopa in uremic patients with the restless legs syndrome

Reuven Sandyk, Charles Bernick, Stanley M. Lee, Lawrence Z. Stern, Robert P. Iacono, Colin R Bamford

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

Original languageEnglish (US)
Pages (from-to)233-235
Number of pages3
JournalInternational Journal of Neuroscience
Volume35
Issue number3-4
DOIs
StatePublished - 1987

Fingerprint

Restless Legs Syndrome
Levodopa
Chronic Kidney Failure
Renal Dialysis
Maintenance
levodopa drug combination carbidopa
Therapeutics

Keywords

  • Chronic renal failure
  • L-dopa
  • Restless legs syndrome

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

L-dopa in uremic patients with the restless legs syndrome. / Sandyk, Reuven; Bernick, Charles; Lee, Stanley M.; Stern, Lawrence Z.; Iacono, Robert P.; Bamford, Colin R.

In: International Journal of Neuroscience, Vol. 35, No. 3-4, 1987, p. 233-235.

Research output: Contribution to journalArticle

Sandyk, Reuven ; Bernick, Charles ; Lee, Stanley M. ; Stern, Lawrence Z. ; Iacono, Robert P. ; Bamford, Colin R. / L-dopa in uremic patients with the restless legs syndrome. In: International Journal of Neuroscience. 1987 ; Vol. 35, No. 3-4. pp. 233-235.
@article{986d9499392444d490b4a336cf12df91,
title = "L-dopa in uremic patients with the restless legs syndrome",
abstract = "Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.",
keywords = "Chronic renal failure, L-dopa, Restless legs syndrome",
author = "Reuven Sandyk and Charles Bernick and Lee, {Stanley M.} and Stern, {Lawrence Z.} and Iacono, {Robert P.} and Bamford, {Colin R}",
year = "1987",
doi = "10.3109/00207458708987132",
language = "English (US)",
volume = "35",
pages = "233--235",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - L-dopa in uremic patients with the restless legs syndrome

AU - Sandyk, Reuven

AU - Bernick, Charles

AU - Lee, Stanley M.

AU - Stern, Lawrence Z.

AU - Iacono, Robert P.

AU - Bamford, Colin R

PY - 1987

Y1 - 1987

N2 - Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

AB - Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

KW - Chronic renal failure

KW - L-dopa

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=0023391259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023391259&partnerID=8YFLogxK

U2 - 10.3109/00207458708987132

DO - 10.3109/00207458708987132

M3 - Article

C2 - 3654080

AN - SCOPUS:0023391259

VL - 35

SP - 233

EP - 235

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 3-4

ER -